Farmacología de dabigatrán y su manejo clínico

Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Rowan, 2007, Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database, J Am Coll Cardiol, 49, 1561, 10.1016/j.jacc.2006.11.045 Nieuwlaat, 2006, Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation, Eur Heart J, 27, 3018, 10.1093/eurheartj/ehl015 Ogilvie, 2010, Underuse of oral anticoagulants in atrial fibrillation: a systematic review, Am J Med, 123, 638, 10.1016/j.amjmed.2009.11.025 Mant, 2007, Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, Lancet, 370, 493, 10.1016/S0140-6736(07)61233-1 Kalra, 2000, Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness, BMJ, 320, 1236, 10.1136/bmj.320.7244.1236 Go, 2003, Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation, JAMA, 290, 2685, 10.1001/jama.290.20.2685 Matchar, 2002, Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial, Am J Med, 113, 42, 10.1016/S0002-9343(02)01131-2 Hylek, 2003, Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation, N Engl J Med, 349, 1019, 10.1056/NEJMoa022913 Garcia, 2010, The new oral anticoagulants, Blood, 115, 15, 10.1182/blood-2009-09-241851 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Stangier, 2007, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, Br J Clin Pharmacol, 64, 292, 10.1111/j.1365-2125.2007.02899.x Blech, 2008, The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans, Drug Metab Dispos, 36, 386, 10.1124/dmd.107.019083 Hankey, 2011, Dabigatran etexilate: a new oral thrombin inhibitor, Circulation, 123, 1436, 10.1161/CIRCULATIONAHA.110.004424 Eisert, 2010, Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin, Arterioscler Thromb Vasc Biol, 30, 1885, 10.1161/ATVBAHA.110.203604 Konkle, 2008, Hemostasis, thrombosis, fibrinolysis and cardiovascular disease, 2049 Rocha, 2001, Inhibidores directos de la trombina: su papel en el tratamiento de la trombosis arterial y venosa, Med Clin (Barc), 116, 63, 10.1016/S0025-7753(01)71721-6 Weitz, 1998, Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors, Circulation, 97, 544, 10.1161/01.CIR.97.6.544 Huntington, 2003, Targeting thrombin —rational drug design from natural mechanisms, Trends Pharmacol Sci, 24, 589, 10.1016/j.tips.2003.09.002 Stubbs, 1993, A player of many parts: the spotlight falls on thrombin's structure, Thromb Res, 69, 1, 10.1016/0049-3848(93)90002-6 Bates, 1998, Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin, Am J Cardiol, 82, P12, 10.1016/S0002-9149(98)00660-2 Di Nisio, 2005, Direct thrombin inhibitors, N Engl J Med, 353, 1028, 10.1056/NEJMra044440 Eriksson, 2009, Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development, Clin Pharmacokinet, 48, 1, 10.2165/0003088-200948010-00001 Stangier, 2010, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study, Clin Pharmacokinet, 49, 259, 10.2165/11318170-000000000-00000 Van Ryn, 2010, Dabigatran etexilate —a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost, 103, 1116, 10.1160/TH09-11-0758 Wienen, 2007, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, Thromb Haemost, 98, 155, 10.1160/TH07-03-0183 Ficha técnica Pradaxa. EMEA, agosto 2010. Disponible en: www.ema.europa.eu. Stangier, 2008, Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate, Clin Pharmacokinet, 47, 285, 10.2165/00003088-200847050-00001 Troconiz, 2007, Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery, J Clin Pharmacol, 47, 371, 10.1177/0091270006297228 Stangier, 2011, Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin, J Clin Pharmacol Stangier, 2009, Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics, Am J Cardiovasc Drugs, 9, 59, 10.1007/BF03256595 Liesenfeld, 2011, Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial, J Thromb Haemost, 9, 2168, 10.1111/j.1538-7836.2011.04498.x Ezekowitz, 2007, Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study), Am J Cardiol, 100, 1419, 10.1016/j.amjcard.2007.06.034 Eikelboom, 2011, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, Circulation, 123, 2363, 10.1161/CIRCULATIONAHA.110.004747 Dans, 2011, RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trial, Eur Heart J, 32, 1 Oldgren, 2011, Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial, Eur Heart J, 32, 2781, 10.1093/eurheartj/ehr113 Wallentin, 2010, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4 Connolly, 2010, Newly identified events in the RE-LY trial, N Engl J Med, 363, 1875, 10.1056/NEJMc1007378 Gage, 2009, Can we rely on RE-LY?, N Engl J Med, 361, 1200, 10.1056/NEJMe0906886 Lip, 2010, Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?, Am J Med, 123, 785, 10.1016/j.amjmed.2010.01.031 Wann, 2011, 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Heart Rhythm, 8, e1, 10.1016/j.hrthm.2011.01.032 Beasley, 2011, Anticoagulant options —Why the FDA approved a higher but not a lower dose of dabigatran, N Engl J Med, 364, 1788, 10.1056/NEJMp1103050 Agencia Española de Medicamentos y Productos Sanitarios. Dabigatrán (Pradaxa®) y riesgo de hemorragia: nuevas recomendaciones de vigilancia de la función renal. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011/docs/NI-MUH_21-2011.pdf. Stangier, 2008, Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects, Clin Pharmacokinet, 47, 47, 10.2165/00003088-200847010-00005 Wolowacz, 2011, Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery, Expert Rev Pharmacoecon Outcomes Res, 11, 9, 10.1586/erp.10.89 Legrand, 2011, The use of dabigatran in elderly patients, Arch Intern Med, 171, 1285, 10.1001/archinternmed.2011.314 Pisters, 2010, A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134 Winkle, 2011, The use of dabigatran immediately after atrial fibrillation ablation, J Cardiovasc Electrophysiol Bassiouny, 2011, Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation: a new paradigm in peri-procedural anticoagulation, Circulation, 124, A13128 Crowther, 2009, Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents, J Thromb Haemost, 7, 107, 10.1111/j.1538-7836.2009.03429.x Wienen, 2008, Efect of recombinant factor VIIa or activated prothrombin complex concentrate on the bleeding time in anaesthetized rats during anticoagulant treatment with the direct thrombin inhibitor dabigatran, J Thromb Haemost, 3, P1703 Eerenberg, 2011, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects, Circulation, 124, 1573, 10.1161/CIRCULATIONAHA.111.029017